Thus, it is likely that the inhibition of CD103+ DCs with HMGB-1 inhibitor may be a potential therapeutic approach to attenuate kidney inflammation and injury in CD103+ DCs mediated CKD, such as AN and DN. The gene discussed is HMGB1; the disease is liver dysplastic nodule.